Emergence of the CD226 Axis in Cancer Immunotherapy
Open Access
- 24 June 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 914406
Abstract
In recent years, a set of immune receptors that interact with members of the nectin/nectin-like (necl) family has garnered significant attention as possible points of manipulation in cancer. Central to this axis, CD226, TIGIT, and CD96 represent ligand (CD155)-competitive co-stimulatory/inhibitory receptors, analogous to the CTLA-4/B7/CD28 tripartite. The identification of PVRIG (CD112R) and CD112 has introduced complexity and enabled additional nodes of therapeutic intervention. By virtue of the clinical progression of TIGIT antagonists and emergence of novel CD96- and PVRIG-based approaches, our overall understanding of the ‘CD226 axis’ in cancer immunotherapy is starting to take shape. However, several questions remain regarding the unique characteristics of, and mechanistic interplay between, each receptor-ligand pair. This review provides an overview of the CD226 axis in the context of cancer, with a focus on the status of immunotherapeutic strategies (TIGIT, CD96, and PVRIG) and their underlying biology (i.e.,cis/transinteractions). We also integrate our emerging knowledge of the immune populations involved, key considerations for Fc gamma (γ) receptor biology in therapeutic activity, and a snapshot of the rapidly evolving clinical landscape.Keywords
This publication has 176 references indexed in Scilit:
- Structure of Nectin-2 reveals determinants of homophilic and heterophilic interactions that control cell–cell adhesionProceedings of the National Academy of Sciences, 2012
- Nectin ectodomain structures reveal a canonical adhesive interfaceNature Structural & Molecular Biology, 2012
- Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clusteringProceedings of the National Academy of Sciences, 2012
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences, 2009
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DCEuropean Journal of Immunology, 2009
- Adaptive immune features of natural killer cellsNature, 2009
- DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumorsJournal of Experimental Medicine, 2008
- Accelerated tumor growth in mice deficient in DNAM-1 receptorJournal of Experimental Medicine, 2008
- CD226 Gly307Ser association with multiple autoimmune diseasesGenes & Immunity, 2008
- CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemiaProceedings of the National Academy of Sciences, 2007